Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 14/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PRKAB2 | O43741 | 4/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 4/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 4/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 4/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763438 | 0.77 | HCAR2 (0.63) | HCAR2TDP1KMT2ATSHR | |
| SCHEMBL22424292 | 0.76 | KDM4C (0.49) | HCAR2KMT2ATSHR | |
| SCHEMBL24423821 | 0.74 | HCAR2 (0.59) | HCAR2TDP1KMT2ATSHR | |
| SCHEMBL948870 | 0.74 | HCAR2 (1.00) | HCAR2KMT2A | |
| SCHEMBL12263262 | 0.74 | HCAR2 (0.55) | HCAR2KMT2ATSHR | |
| SCHEMBL17351765 | 0.70 | HCAR2 (0.35) | HCAR2TDP1PRKAA1 | |
| SCHEMBL28835744 | 0.69 | HCAR2 (0.65) | HCAR2 | |
| SCHEMBL2762562 | 0.69 | HCAR2 (0.53) | HCAR2TDP1KMT2ATSHR | |
| SCHEMBL30300414 | 0.69 | HCAR2 (0.58) | HCAR2KMT2APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL27764731 | 0.69 | HCAR2 (0.53) | HCAR2TDP1KMT2APRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809344-B2 | Compounds, compositions, and methods for control of hepatitis C viral infections | APATH, LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809344-B2 | Compounds, compositions, and methods for control of hepatitis C viral infections | APATH, LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809344-B2 | Compounds, compositions, and methods for control of hepatitis C viral infections | APATH, LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110262397-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROL OF HEPATITIS C VIRAL INFECTIONS | APATH, LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262397-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROL OF HEPATITIS C VIRAL INFECTIONS | APATH, LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262397-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROL OF HEPATITIS C VIRAL INFECTIONS | APATH, LLC (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010096115-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROL OF HEPATITIS C VIRAL INFECTIONS | APATH, LLC (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010096115-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROL OF HEPATITIS C VIRAL INFECTIONS | APATH, LLC (US) | 2010-08-26 | — | — | WO | disclosed |
| EP-0269436-B2 | Silver halide color photographic light-sensitive material containing pyrazoloazole type cyan coupler | KONISHIROKU PHOTO IND (JP) | 1994-11-02 | — | — | EP | disclosed |
| US-4873183-A | CONTAINED IN RED-SENSITIVE LAYER; SHARP ABSORPTION SPECTRA WITH REDUCTION OF GREEN ABSORPTION; HEAT AND MOISTURE RESISTANCE | KONICA CORPORATION (JP) | 1989-10-10 | — | — | US | disclosed |
| EP-0269436-A2 | Silver halide color photographic light-sensitive material containing pyrazoloazole type cyan coupler | KONICA CORPORATION (JP) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262397-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROL OF HEPATITIS C VIRAL INFECTIONS | HAVCR2, FABP1, HCCS | HCAR2 2570/4885TDP1 1627/4885KMT2A 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.